Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.11 USD | +2.82% | +24.03% | +21.09% |
Apr. 19 | Butler Hall Capital urges Vanda to engage in sales discussions | RE |
Apr. 17 | Deals of the day-Mergers and acquisitions | RE |
Financials (USD)
Sales 2022 | 254M | Sales 2023 | 193M | Capitalization | 243M |
---|---|---|---|---|---|
Net income 2022 | 6M | Net income 2023 | 2M | EV / Sales 2022 | -0.15 x |
Net cash position 2022 | 456M | Net cash position 2023 | 379M | EV / Sales 2023 | -0.71 x |
P/E ratio 2022 |
67.2
x | P/E ratio 2023 |
106
x | Employees | 203 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.79% |
Latest transcript on Vanda Pharmaceuticals Inc.
1 day | +2.82% | ||
1 week | +24.03% | ||
Current month | +24.33% | ||
1 month | +35.90% | ||
3 months | +39.62% | ||
6 months | +18.56% | ||
Current year | +21.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard W. Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
Chief Executive Officer | 64 | 02-10-31 | |
Director/Board Member | 72 | 20-02-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.34% | 29 M€ | -5.60% | ||
0.22% | 27 M€ | -5.75% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 5.11 | +2.82% | 2,440,757 |
24-04-18 | 4.97 | -5.15% | 3,859,528 |
24-04-17 | 5.24 | +29.38% | 24,035,651 |
24-04-16 | 4.05 | -0.25% | 790,418 |
24-04-15 | 4.06 | -1.46% | 787,157 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+21.09% | 294M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- VNDA Stock